- A Senior Vice President at ANI Pharmaceuticals Inc. executed an insider stock sale of 500 shares.
- Global Alpha Capital Management Ltd. significantly reduced its position in ANI Pharmaceuticals Inc. by selling nearly 229,000 shares.
- Despite these sales, ANI Pharmaceuticals Inc. reported strong Q1 2026 financial results, including adjusted EPS of $2.05 and revenues of $237.50 million, leading to a raised full-year outlook.
ANI Pharmaceuticals Inc. (NASDAQ: ANIP) is a pharmaceutical company that develops, manufactures, and markets prescription drugs. The company focuses on both branded products, particularly for rare diseases, and generic medications. It operates in a competitive industry, producing a diverse portfolio of treatments for the market.
The central event involves an insider transaction on May 13, 2026. Cook Meredith, a Senior Vice President at ANI Pharmaceuticals Inc., sold 500 shares of company stock at a price of $78.16 per share. An insider sale occurs when an executive sells their own company’s stock. After this sale, Meredith’s ownership stands at 78,390 shares.
This sale follows a larger transaction by an institutional investor. During the first quarter, Global Alpha Capital Management Ltd. sold nearly 229,000 shares of ANI Pharmaceuticals Inc., a sale valued at about $17.87 million. This significantly reduced the investment firm’s position in the company to 1.67% of its managed assets.
Despite these sales, ANI Pharmaceuticals Inc. demonstrates strong financial health. As highlighted by Zacks Investment Research, the company reported excellent first-quarter 2026 results. It posted adjusted earnings per share (EPS) of $2.05 on revenues of $237.50 million, beating analyst estimates. EPS is the portion of a company’s profit allocated to each outstanding share of stock.
This performance was driven by a 42% sales increase in its Purified Cortrophin Gel. Due to the strong quarter, ANI Pharmaceuticals Inc. raised its 2026 outlook. The company now expects revenues between $1.08 billion and $1.14 billion, with an updated EPS forecast in the range of $9.19 to $9.69 for the full year.
